Colin Gibson was born in the Scottish border town of Hawick, famous for its rugby football and knitting industry. The family moved to Godalming near Guildford in deepest Southern England when he was ten years old.
He went to Southampton University for his B.Sc. studies and stayed there to carry out Ph.D research with Professor Ray Baker, FRS. This work involved initially the analysis of insect hormones but mainly involved the total synthesis of a number of natural products.
After Southampton, Colin was awarded a University of Melbourne research fellowship in Australia. Here he spent a very enjoyable two years working with Professor Don Cameron on the synthesis of quinone natural products as well as visiting relatives.
On returning to the UK he took up a post doctoral research associateship with Professor Sir Alan Battersby, FRS at the University Chemical Laboratory in Cambridge on the synthesis of putative intermediates in vitamin B12 biosynthesis. This was followed by a Senior Research Fellowship at Christ's College, Cambridge.
The heady heights of Cambridge were followed by short interlude at Surrey University as a member of Faculty.
In 1991 he made the move back to Scotland and joined the Strathclyde Chemistry Department.
In his spare time he enjoys watching Hawick RFC playing, drinking wine, cycling (occasional mountain biking) and walking, particularly on the Island of Arran.
- Synthesis of Inhibitors and Activators of Pterin Related Enzymes
- Pure and applied chemistry (Journal)
- Guest editor
- Sustainable Laboratory Chemistry
- Keynote/plenary speaker
- ICHC 2011 Conference
- Current Org. Synth.
- Editorial board member
- Examiner for Ph.D. degree, Manchester, St. Andrews and Faisalabad
- External Examiner
more professional activities
- Impact Acceleration Account - University Of Strathclyde 2012 / RA8926
- Gibson, Colin (Principal Investigator)
- Period 01-Feb-2015 - 30-Sep-2015
- ANTI-PARASITIC PYRROLOPYRIMIDINES
- Suckling, Colin (Principal Investigator) Gibson, Colin (Co-investigator)
- Parasitic diseases, including malaria, leishmaniasis, and trypanosomiasis are amongst the most prevalent diseases world wide collectively with the poorest availability of effective drugs. Human African trypanosomiasis (HAT) has been reported to have a greater morbidity and mortality than HIV/AIDS in some locations. Parasitic disease is difficult to treat because the parasites become closely connected with the living host and it is therefore difficult to find drugs that attack only the parasite. Available drugs are few and are also toxic to humans. In laboratory experiments, we have shown that novel compounds designed and prepared in at the University of Strathclyde and University of Dundee are potentially able to fill the gap in drug availability. Our project is to optimise the effectiveness of our compounds to provide candidate drugs for full clinical development.
- Period 01-Oct-2010 - 31-Dec-2013
Pure and Applied Chemistry
Thomas Graham Building
View University of Strathclyde in a larger map